Physician profile
Michael Bays
NPI 1134101090
$4,180.77
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $800 · 2020: $472 · 2021: $923 · 2022: $1,286 · 2023: $685 · 2024: $14.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $699.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,812.78 | 2019-2023 | Linzess, Rinvoq, Creon |
| Janssen Biotech, INC. | $528.77 | 2019-2023 | Simponi, Simponi Aria, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $506.27 | 2019-2023 | Xifaxan |
| Celgene Corporation | $171.52 | 2021-2023 | Zeposia |
| Daiichi Sankyo INC. | $144.21 | 2020-2023 | Injectafer |
| Pfizer INC. | $124.58 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $122.86 | 2019-2023 | Entyvio |
| Boston Scientific Corporation | $110.40 | 2019-2024 | Cre Pro, Compliance Endokit, Advanix Biliary |
| Janssen Scientific Affairs, LLC | $98.00 | 2019 | |
| Apollo Endosurgery US INC | $70.76 | 2019 | |
| Shionogi INC | $57.79 | 2019 | |
| Gilead Sciences, INC. | $57.69 | 2021-2023 | |
| Qol Medical, LLC | $52.53 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $45.97 | 2020-2022 | |
| Genzyme Corporation | $45.92 | 2022-2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $43.45 | 2022-2023 | Dupixent |
| Intuitive Surgical, INC. | $35.70 | 2019 | |
| Shire North American Group INC | $33.32 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $32.60 | 2022 | |
| Lucid Diagnostics INC. | $29.64 | 2023 | |
| Redhill Biopharma INC. | $29.49 | 2021 | |
| Intercept Pharmaceuticals, INC. | $15.65 | 2021 | |
| Dova Pharmaceuticals | $10.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bays listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.